The Motley Fool
13 Jun 2026, 04:15 UTC · 13w ago
Verdict
Headline leans bullish. We score BSX −0.80 across four claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Boston Scientific CEO Michael Mahoney indicated the company will likely report flat dollar growth for the second and third quarters.
More negative than 92% of claims this week
Boston Scientific has repeatedly lowered organic revenue guidance throughout the year, most recently reducing the 2026 outlook to between 6.5% and 8%.
Continue reading
5 related stories
More negative than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 86% of claims this week
The decline in growth is partially attributed to the decreasing usage of Watchman stand-alone heart implant procedures.
More negative than 73% of claims this week
Despite the stock's decline, 27 out of 31 analysts maintain a buy rating with a consensus price target of $78, suggesting a potential 65% upside.
More positive than 54% of claims this week
Which stocks this story touches
More negative than 88% of ticker scores this week
The company has seen significant share price declines and has repeatedly lowered growth expectations and revenue guidance.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a peer for valuation comparison and as a recommended holding by the author's firm.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a peer for valuation comparison and as a recommended holding by the author's firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
55m ago
More positive than 36% of relationship scores this week
[mutual] Boston Scientific is compared to Abbott Laboratories as being in the same medical device stock category.
More positive than 36% of relationship scores this week
[mutual] Boston Scientific is compared to Medtronic as being in the same medical device stock category.
−7.2%
Price agrees with the score
$43.55 vs $46.91 close before publication (Jun 12) · not market-adjusted
BSX chart →
